{"page_content": "1 9 01 15/08/24\n\nAnnika Maria Kuzikov Jenmalm Jensen/ Kun Philip Gribbon Qian annika.jenmalm- maria.kuzikov@itmp.fraunhofer.de jensen@ki.se/ Philip.Gribbon@itmp.fraunhofer.de kun.qian@ki.se 31/07/24 15/08/2024 DD/MM/YY\n\n1 Index\n\nIndex ........................................................................................................................................................ 1 Goal and Area of Application ................................................................................................................... 2 Definitions and Abbreviations ................................................................................................................. 2 4 Method .................................................................................................................................................... 2 General ............................................................................................................................................ 2 Information for consumables / chemicals / equipment ...................................................................... 2 Procedure......................................................................................................................................... 3 Further applicable resources .................................................................................................................... 8 Document history .................................................................................................................................... 8 Annex ...................................................................................................................................................... 8\n\n1\n\n2\n\n3\n\n5\n\n6\n\n7\n\nR4ALL - SOP \u2013 Detection of Drug-Induced-Phospholipidosis\n\nPage: 1/9\n\n2 9 01 15/08/24\n\n2 Goal and Area of Application\n\nPhospholipidosis is a storage disorder of excessive accumulation of phospholipids in lysosomes that can be drug-induced. understanding the role of drug-induced phospholipidosis (DIPL) in ongoing drug screenings is necessary to better to distinguish between on-target and side effects as well as for putative endosomal pathway disturbance.", "metadata": {"doc_id": "bea4e4be-e218-42a2-b3cd-0354096c6d4c", "content_type": "CompositeElement", "filename": "ANNEX3_R4ALL_SOP_DIPL-phospholipidosis.pdf"}}